75.25
price down icon0.27%   -0.20
pre-market  プレマーケット:  75.22   -0.03   -0.04%
loading
前日終値:
$75.45
開ける:
$75.84
24時間の取引高:
850.25K
Relative Volume:
0.40
時価総額:
$12.44B
収益:
$1.06B
当期純損益:
$-326.58M
株価収益率:
-35.80
EPS:
-2.1022
ネットキャッシュフロー:
$-977.73M
1週間 パフォーマンス:
+4.83%
1か月 パフォーマンス:
+0.62%
6か月 パフォーマンス:
+0.76%
1年 パフォーマンス:
+123.66%
1日の値動き範囲:
Value
$74.82
$76.96
1週間の範囲:
Value
$71.30
$77.76
52週間の値動き範囲:
Value
$31.66
$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1106)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
1,402
Name
Twitter
@ionispharma
Name
次回の収益日
2026-04-29
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IONS icon
IONS
Ionis Pharmaceuticals Inc
75.25 12.44B 1.06B -326.58M -977.73M -2.1022
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 107.87B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 73.63B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 49.42B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 40.20B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.06B 5.36B 287.73M 924.18M 2.5229

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-21 開始されました Canaccord Genuity Buy
2026-04-10 再開されました Raymond James Outperform
2026-01-28 再開されました Barclays Overweight
2025-10-08 アップグレード JP Morgan Neutral → Overweight
2025-09-26 アップグレード Goldman Sell → Neutral
2025-09-03 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-31 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-07-01 アップグレード Barclays Equal Weight → Overweight
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
May 04, 2026

MSN Money - MSN

May 04, 2026
pulisher
May 04, 2026

Form 144: Option exercises listed; Joseph Loscalzo sold shares (IONS) - Stock Titan

May 04, 2026
pulisher
May 04, 2026

Ionis well-positioned for continued momentum and substantial valu - The National Law Review

May 04, 2026
pulisher
May 04, 2026

Ionis to host 2026 virtual Annual Meeting of Stockholders - BioSpace

May 04, 2026
pulisher
May 04, 2026

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market - openPR.com

May 04, 2026
pulisher
May 03, 2026

Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com

May 03, 2026
pulisher
May 03, 2026

Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks - TipRanks

May 03, 2026
pulisher
May 03, 2026

Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus

May 03, 2026
pulisher
May 03, 2026

Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

May 03, 2026
pulisher
May 03, 2026

Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

May 03, 2026
pulisher
May 02, 2026

Discipline and Rules-Based Execution in IONS Response - Stock Traders Daily

May 02, 2026
pulisher
May 02, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen - MarketBeat

May 02, 2026
pulisher
May 01, 2026

VY(R) T. Rowe Price Diversified Mid Cap Growth Portfolio's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Teladoc (TDOC) - The Globe and Mail

May 01, 2026
pulisher
May 01, 2026

Ionis Pharmaceuticals | SCHEDULE 13G: Others - Moomoo

May 01, 2026
pulisher
May 01, 2026

Ionis to present at upcoming investor conferences - The National Law Review

May 01, 2026
pulisher
May 01, 2026

Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st

May 01, 2026
pulisher
May 01, 2026

Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold - Moomoo

May 01, 2026
pulisher
May 01, 2026

Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

May 01, 2026
pulisher
May 01, 2026

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Ionis Pharmaceuticals (IONS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail

May 01, 2026
pulisher
May 01, 2026

IONS Maintained by Barclays -- Price Target Raised to $115 - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Atle Fund Management AB's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Ionis Pharmaceuticals Projects Ozarsen Sales Exceeding 3 Billion Dollars - HarianBasis.co

May 01, 2026
pulisher
Apr 30, 2026

Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com

Apr 30, 2026
pulisher
Apr 30, 2026

Narrow-Moat Ionis' Peak Sales Raised for Olezarsen; Positive Outlook as Late-Stage Assets Advance - Morningstar

Apr 30, 2026
pulisher
Apr 30, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

IONS Maintained by RBC Capital -- Price Target Raised to $100 - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.

Apr 30, 2026
pulisher
Apr 30, 2026

Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Vanguard reports 5.05% stake in Ionis Pharmaceuticals (NASDAQ: IONS) - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View - TradingView

Apr 30, 2026
pulisher
Apr 30, 2026

Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $86 - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $100 to $125 - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 30, 2026
pulisher
Apr 30, 2026

Ionis Pharmaceuticals Q1 2026 earnings preview - MSN

Apr 30, 2026
pulisher
Apr 30, 2026

IONS Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Ionis Pharmaceuticals Inc (IONS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity By Investing.com - Investing.com India

Apr 30, 2026
pulisher
Apr 30, 2026

IONS SWOT Analysis: Strong Revenue Growth Amidst Challenges Reve - GuruFocus

Apr 30, 2026
pulisher
Apr 29, 2026

Ionis Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IONS) 2026-04-29 - Seeking Alpha

Apr 29, 2026
pulisher
Apr 29, 2026

Oppenheimer raises Ionis Pharmaceuticals price target on guidance By Investing.com - Investing.com Canada

Apr 29, 2026
pulisher
Apr 29, 2026

Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity - Investing.com

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis outlines 2026 revenue of $875M-$900M while lifting olezarsen peak sales view to >$3B - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c) - TipRanks

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M - TipRanks

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Issues Quarterly Earnings Results - MarketBeat

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis gains on late-stage trial win for hypertriglyceridemia therapy - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

Ionis Pharmaceuticals Q1: Revenue $246.1M, EPS (loss) $0.56 — 10-Q Summary - TradingView

Apr 29, 2026

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ionis Pharmaceuticals Inc (IONS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
KLEIN JOSEPH III
Director
May 01 '26
Sale
73.51
10,111
743,238
11,014
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):